Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, maintains that Sanofi-Aventis’ docetaxel follow-on Jevtana (cabazitaxel) is too costly for treating prostate cancer patients on the National Health Service. Final negative draft guidance comes even though the institute changed its mind and recognised that the drug does in fact meet NICE's end-of-life criteria that gives it more scope to consider expensive drugs.
You may also be interested in...
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.